Acetium
|
New Acetium capsule reduces carcinogenic acetaldehyde The new Acetium capsule, developed by Biohit Oyj/Finland, reduces carcinogenic acetaldehyde in the stomach. This over-the-counter product will be available in pharmacies in Finland from May 26th 2010. |
![]() |
|
The Acetium capsule is recommended for people who have low-acid or acid-free stomachs, suffer from chronic Helicobacter pylori infections or are undergoing long-term treatment with medications that reduce gastric acid secretion (PPI drugs and H2 blockers), since microbes produce acetaldehyde in acid-free stomachs. In addition, acetaldehyde in tobacco smoke reaches the stomach by dissolving in the smoker’s saliva. An acid-free stomach, a Helicobacter pylori infection and smoking are the most important risk factors for stomach cancer. Furthermore, an acid-free stomach and smoking are also independent risk factors for oesophageal cancer. In collaboration with University of Helsinki scientists and in-house scientific advisers, Biohit has developed an array of methods which significantly help reduce the exposure of the gastrointestinal tract (mouth, pharynx, oesophagus and stomach) to carcinogenic acetaldehyde. The company has pending and granted patents in several countries. Read more about Acetium:
Other articles: Literature:
More related literature | |



